Page 102 - Read Online
P. 102

Zhang et al. Cancer Drug Resist 2024;7:34  https://dx.doi.org/10.20517/cdr.2024.59  Page 13 of 20

               leveraging ChatGPT automated development and analysis (ADA) technology to build machine learning
                                                 [201]
               models based on real clinical trial data  can facilitate efficient research on cancer precision treatment,
               prognosis, and drug resistance markers.

               DECLARATIONS
               Acknowledgments
               We appreciate and acknowledge the support from Dr. Rensen Ran and Lei Chen for their guidance and
               assistance in drawing.

               Authors’ contributions
               Conceived the contents and structure: Yang S, Deng F, Yang X, Li A, Xia W, Gao C, Lei S
               Wrote the original manuscript: Zhang Y, Peng Y, Lin B
               Revised and improved the manuscript: Liao W, Zeng Q
               All authors have read and agreed to the published version of the manuscript.


               Availability of data and materials
               Not applicable.

               Financial support and sponsorship
               Project of Administration of Traditional  Chinese Medicine of Guangdong Province of China (No.
               20231070).

               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               Not applicable.
               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2024.


               REFERENCES
               1.       Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal
                    Transduct Target Ther 2023;8:31.  DOI  PubMed  PMC
               2.       Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J
                    Natl Compr Canc Netw 2020;18:873-98.  DOI  PubMed
               3.       Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. Lancet 2021;398:2289-99.  DOI  PubMed
               4.       Chow LQM. Head and neck cancer. N Engl J Med 2020;382:60-72.  DOI  PubMed
               5.       Wong KCW, Hui EP, Lo KW, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 2021;18:679-95.  DOI
                    PubMed
               6.       Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.  DOI
                    PubMed
               7.       Dai F, Dai L, Zheng X, et al. Non-coding RNAs in drug resistance of head and neck cancers: a review. Biomed Pharmacother
                    2020;127:110231.  DOI  PubMed
               8.       Romano G, Veneziano D, Acunzo M, Croce CM. Small non-coding RNA and cancer. Carcinogenesis 2017;38:485-91.  DOI
                    PubMed  PMC
               9.       Nemeth K, Bayraktar R, Ferracin M, Calin GA. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet
                    2024;25:211-32.  DOI  PubMed
               10.       Patop IL, Wüst S, Kadener S. Past, present, and future of circRNAs. EMBO J 2019;38:e100836.  DOI  PubMed  PMC
               11.       Kabekkodu SP, Shukla V, Varghese VK, D’Souza J, Chakrabarty S, Satyamoorthy K. Clustered miRNAs and their role in biological
                    functions and diseases. Biol Rev Camb Philos Soc 2018;93:1955-86.  DOI  PubMed
               12.       Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol
   97   98   99   100   101   102   103   104   105   106   107